Antioxidant activity and pharmacokinetic profiling of Urtica dioica extract: potential therapeutic applications

Urtica dioica is a medicinal plant widely recognized for its therapeutic potential, particularly due to its potent antioxidant and anti-inflammatory properties. It has been traditionally used in various cultures for managing inflammatory disorders, metabolic syndromes, and neurodegenerative diseases. The plant’s pharmacological significance is largely attributed to its rich composition of bioactive compounds, including flavonoids, phenolic acids, and terpenoids, which contribute to its diverse biological activities.

The phytochemical composition of Urtica dioica extract was analyzed to determine its total phenolic and flavonoid content. Antioxidant activity was assessed using radical scavenging assays, ferric reducing antioxidant power (FRAP), ABTS•+ activity, and β-carotene bleaching inhibition. Pharmacokinetic properties were predicted in silico, evaluating drug-likeness based on Lipinski’s rule of five, gastrointestinal absorption, blood–brain barrier (BBB) permeability, interactions with P-glycoprotein (P-gp), and the inhibition of cytochrome P450 (CYP) isoforms.

Phytochemical analysis confirmed the presence of bioactive compounds contributing to the extract’s strong antioxidant potential, as demonstrated by its high radical scavenging capacity and inhibition of oxidative damage. Pharmacokinetic modeling indicated that the identified compounds exhibited good oral bioavailability, high gastrointestinal absorption, and the ability to cross the BBB, suggesting potential neuroprotective effects. Furthermore, none of the major compounds were substrates for P-gp, and they exhibited minimal inhibition of CYP isoforms, indicating a low risk of drug resistance and interactions.

Urtica dioica demonstrates promising pharmacological potential due to its antioxidant efficacy, favorable pharmacokinetic profile, and neuroprotective properties. These findings support its therapeutic application in oxidative stress-related disorders, including neurodegeneration and chronic inflammation. Further clinical studies are warranted to validate these results and explore its integration into pharmaceutical and nutraceutical formulations.